![]()
|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Papers In Press, published online ahead of print February 27, 2002
Department of Ortopaedic Surgery , Biochemistry & Molecular Biology, University of Southern California, Los Angeles, CA 90033
Corresponding Author: frenkel{at}hsc.usc.edu
Differentiating osteoblasts in culture undergo a commitment stage, during which cobblestone-like cells grow to high density past confluency. In contrast to earlier proliferative stages, the cell cycle during this commitment stage is inhibited by glucocorticoids (GC). Chronic GC treatment also impedes mineral deposition, if steroid administration commences early enough during commitment. The present study defines a role for the glycogen synthase kinase 3ß (GSK3ß) and its target, c-MYC, in the GC-sensitive, osteoblast persistent cell cycle. c-MYC levels decrease as cells reach confluence, but then increase during growth to high density. GC administration at this stage results in down-regulation of c-MYC. This is accompanied by GC-mediated attenuation of GSK3ß Ser9 inhibitory phosphorylation and increased GSK3ß kinase activity. The down-regulation of c-MYC is attributable to enhanced Thr58 phosphorylation, leading to accelerated degradation. In contrast, GC did not inhibit c-MYC synthesis rate or the level of ß-catenin, a transcriptional co-activator of c-myc. The attenuated cell cycle, as well as the reduced c-MYC level, was rescued back to control levels by specific inhibition of GSK3ß using lithium chloride. These results suggest that tonal GSK3ß repression at the cobblestone stage of osteoblast differentiation permits osteoblast growth to high density. GC interfere with this growth-permissive axis by GSK3ß activation, resulting in c-MYC down-regulation and impediment of the G1/S cell cycle transition.
J. Biol. Chem, 10.1074/jbc.M109708200
Submitted on October 9, 2001
Revised on February 27, 2002
Accepted on February 27, 2002
Glucocorticoids inhibit cell cycle progression in differentiating osteoblasts via glycogen synthase kinase
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
S. Takayama, I. Rogatsky, L. E. Schwarcz, and B. D. Darimont The Glucocorticoid Receptor Represses Cyclin D1 by Targeting the Tcf-beta-Catenin Complex J. Biol. Chem., June 30, 2006; 281(26): 17856 - 17863. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Kirton, F. L. Wilkinson, A. E. Canfield, and M. Y. Alexander Dexamethasone Downregulates Calcification-Inhibitor Molecules and Accelerates Osteogenic Differentiation of Vascular Pericytes: Implications for Vascular Calcification Circ. Res., May 26, 2006; 98(10): 1264 - 1272. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Mulholland, S. Dedhar, G. A. Coetzee, and C. C. Nelson Interaction of Nuclear Receptors with the Wnt/{beta}-Catenin/Tcf Signaling Axis: Wnt You Like to Know? Endocr. Rev., December 1, 2005; 26(7): 898 - 915. [Abstract] [Full Text] [PDF] |
||||
![]() |
F.-S. Wang, C.-L. Lin, Y.-J. Chen, C.-J. Wang, K. D. Yang, Y.-T. Huang, Y.-C. Sun, and H.-C. Huang Secreted Frizzled-Related Protein 1 Modulates Glucocorticoid Attenuation of Osteogenic Activities and Bone Mass Endocrinology, May 1, 2005; 146(5): 2415 - 2423. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-F. Iu, H. Kaji, H. Sowa, J. Naito, T. Sugimoto, and K. Chihara Dexamethasone suppresses Smad3 pathway in osteoblastic cells J. Endocrinol., April 1, 2005; 185(1): 131 - 138. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Smith and B. Frenkel Glucocorticoids Inhibit the Transcriptional Activity of LEF/TCF in Differentiating Osteoblasts in a Glycogen Synthase Kinase-3{beta}-dependent and -independent Manner J. Biol. Chem., January 21, 2005; 280(3): 2388 - 2394. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. T. Barata, A. Silva, J. G. Brandao, L. M. Nadler, A. A. Cardoso, and V. A. Boussiotis Activation of PI3K Is Indispensable for Interleukin 7-mediated Viability, Proliferation, Glucose Use, and Growth of T Cell Acute Lymphoblastic Leukemia Cells J. Exp. Med., September 7, 2004; 200(5): 659 - 669. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Takuma, T. Kaneda, T. Sato, S. Ninomiya, M. Kumegawa, and Y. Hakeda Dexamethasone Enhances Osteoclast Formation Synergistically with Transforming Growth Factor-{beta} by Stimulating the Priming of Osteoclast Progenitors for Differentiation into Osteoclasts J. Biol. Chem., November 7, 2003; 278(45): 44667 - 44674. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Luppen, N. Leclerc, T. Noh, A. Barski, A. Khokhar, A. L. Boskey, E. Smith, and B. Frenkel Brief Bone Morphogenetic Protein 2 Treatment of Glucocorticoid-inhibited MC3T3-E1 Osteoblasts Rescues Commitment-associated Cell Cycle and Mineralization without Alteration of Runx2 J. Biol. Chem., November 7, 2003; 278(45): 44995 - 45003. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Engelbrecht, H. de Wet, K. Horsch, C. R. Langeveldt, F. S. Hough, and P. A. Hulley Glucocorticoids Induce Rapid Up-Regulation of Mitogen-Activated Protein Kinase Phosphatase-1 and Dephosphorylation of Extracellular Signal-Regulated Kinase and Impair Proliferation in Human and Mouse Osteoblast Cell Lines Endocrinology, February 1, 2003; 144(2): 412 - 422. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |